Neurodegenerative disorders (NGDs) affect millions worldwide. Resonant develops tests that detect early biomarkers of neurodegeneration, providing researchers, clinicians, & individuals with accessible screening tools to assist with the diagnosis, treatment, and management of NGDs.
Resonant is developing clinical pre-symptomatic blood tests to support the diagnosis of neurodegenerative diseases—Alzheimer’s disease, Parkinson’s disease, and ALS. Our research team has initiated clinical validation of the Alzheimer's disease test with a cohort of 50 human blood samples and is planning a larger validation study of 1,700 patient samples across the 3 disease states beginning in Q3’2024. In this larger study, Resonant plans on validating the three individual blood tests for Alzheimer's, Parkinson's, and ALS as well as a combined blood panel capable of identifying the three biomarkers from a single blood sample
The individual assays are currently available for research use. We are also exploring companion diagnostic opportunities with BioPharma partners seeking to add biomarkers of neuron type-specific cell death as an end-point in their therapeutic studies.
Join our research waitlist to participate in future studies. We are excited at the prospect of your involvement.
Learn More
Upcoming solutions for healthcare
institutions, payers, and individual practices. These will evovle in tandem.
Dying neurons release DNA into the blood. Determining the DNA’s neuron of origin can give us insight into neurodegeneration in the brain.
The neuron-of-origin can be identified by chemical DNA modifications called methylations. Resonant uses a powerful targeted technology that allows us to analyze regions of DNA with neuron type specific patterns of methylation.
Neurodegenerative diseases are associated with the death of specific types of neurons:
Cortical neurons & Alzheimer's disease
Dopaminergic neurons & Parkinson's disease
Spinal motor neurons & ALS
We're currently validating the correlation between elevated neuron DNA in the blood and disease development using blood samples from patients with Alzheimer's, Parkinson's, and ALS.
Neurodegenerative diseases affect millions worldwide. Existing diagnostic tools lack the necessary sensitivity and accessibility to fundamentally transform the way we detect, treat, and manage neurodegenerative diseases. To us, earlier diagnosis means earlier access to clinical trials and therapeutics. It also means more time—time to make informed decisions and time to plan ahead. We envision a future where patients with neurodegenerative diseases have the option to take their health into their own hands and have the time to plan for their futures.
